Page 1446 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 79 Marginal Zone Lymphomas (Extranodal/Malt, Splenic, and Nodal) 1287.e5

167. Corradini P, Ladetto M, Zallio F, et al: Long-term follow-up of indolent 187. Baseggio L, Traverse-Glehen A, Petinataud F, et al: CD5 expression
lymphoma patients treated with high-dose sequential chemotherapy identifies a subset of splenic marginal zone lymphomas with higher
and autografting: evidence that durable molecular and clinical remis- lymphocytosis: a clinico-pathological, cytogenetic and molecular study
sion frequently can be attained only in follicular subtypes. J Clin Oncol of 24 cases. Haematologica 95:604, 2010.
22:1460, 2004. 188. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al: Splenic marginal
168. Escalon MP, Champlin RE, Saliba RM, et al: Nonmyeloablative zone lymphoma: proposal of new diagnostic and prognostic markers
allogeneic hematopoietic transplantation: a promising salvage therapy identified after tissue and cDNA microarray analysis. Blood 106:1831,
for patients with non-Hodgkin’s lymphoma whose disease has failed a 2005.
prior autologous transplantation. J Clin Oncol 22:2419, 2004. 189. Algara P, Mateo MS, Sanchez-Beato M, et al: Analysis of the IgV(H)
169. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow somatic mutations in splenic marginal zone lymphoma defines a group
transplantation in 69 patients with a history of low-grade B-cell non- of unmutated cases with frequent 7q deletion and adverse clinical
Hodgkin’s lymphoma. Blood 77:2524, 1991. course. Blood 99:1299, 2002.
170. Freytes CO, Loberiza FR, Rizzo JD, et al: Myeloablative allogeneic 190. Novara F, Arcaini L, Merli M, et al: High-resolution genome-wide array
hematopoietic stem cell transplantation in patients who experience comparative genomic hybridization in splenic marginal zone B-cell
relapse after autologous stem cell transplantation for lymphoma: a lymphoma. Hum Pathol 40:1628, 2009.
report of the International Bone Marrow Transplant Registry. Blood 191. Zhu D, Orchard J, Oscier DG, et al: V(H) gene analysis of splenic
104:3797, 2004. marginal zone lymphomas reveals diversity in mutational status and
171. Morris E, Thomson K, Craddock C, et al: Outcomes after initiation of somatic mutation in vivo. Blood 100:2659, 2002.
alemtuzumab-containing reduced-intensity allogeneic transplantation 192. Tiacci E, Trifonov V, Schiavoni G, et al: BRAF mutations in hairy-cell
regimen for relapsed and refractory non-Hodgkin lymphoma. Blood leukemia. N Engl J Med 364:2305, 2011.
104:3865, 2004. 193. Gachard N, Parrens M, Soubeyran I, et al: IGHV gene features and
172. Li L, Bierman P, Vose J, et al: High-dose therapy/autologous hema- MYD88 L265P mutation separate the three marginal zone lymphoma
topoietic stem cell transplantation in relapsed or refractory marginal entities and Waldenström macroglobulinemia/lymphoplasmacytic
zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 11:253, lymphomas. Leukemia 27:183, 2013.
2011. 194. Troussard X, Valensi F, Duchayne E, et al: Splenic lymphoma with
173. A predictive model for aggressive non-Hodgkin’s lymphoma. The villous lymphocytes: clinical presentation, biology and prognostic
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. factors in a series of 100 patients. Groupe Francais d’Hematologie
N Engl J Med 329:987, 1993. Cellulaire (GFHC). Br J Haematol 93:731, 1996.
174. Castrillo JM, Montalban C, Abraira V, et al: Evaluation of the inter- 195. Mulligan SP, Matutes E, Dearden C, et al: Splenic lymphoma with
national index in the prognosis of high grade gastric malt lymphoma. villous lymphocytes: natural history and response to therapy in 50 cases.
Leuk Lymphoma 24:159, 1996. Br J Haematol 78:206, 1991.
175. Bastion Y, Coiffier B: Is the International Prognostic Index for Aggres- 196. Tsimberidou AM, Catovsky D, Schlette E, et al: Outcomes in patients
sive Lymphoma patients useful for follicular lymphoma patients? J Clin with splenic marginal zone lymphoma and marginal zone lymphoma
Oncol 12:1340, 1994. treated with rituximab with or without chemotherapy or chemotherapy
176. Cortelazzo S, Rossi A, Oldani E, et al: The modified International Prog- alone. Cancer 107:125, 2006.
nostic Index can predict the outcome of localized primary intestinal 197. Bennett M, Sharma K, Yegena S, et al: Rituximab monotherapy for
lymphoma of both extranodal marginal zone B-cell and diffuse large splenic marginal zone lymphoma. Haematologica 90:856, 2005.
B-cell histologies. Br J Haematol 118:218, 2002. 198. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al: Treatment of
177. Sagaert X, de Paepe P, Libbrecht L, et al: Forkhead box protein P1 splenic marginal zone lymphoma with rituximab monotherapy: pro-
expression in mucosa-associated lymphoid tissue lymphomas predicts gress report and comparison with splenectomy. Oncologist 18:190,
poor prognosis and transformation to diffuse large B-cell lymphoma. J 2013.
Clin Oncol 24:2490, 2006. 199. Thieblemont C, Felman P, Callet-Bauchu E, et al: Splenic marginal-
178. Arcaini L, Lazzarino M, Colombo N, et al: Splenic marginal zone zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol
lymphoma: a prognostic model for clinical use. Blood 107:4643, 4:95, 2003.
2006. 200. Crary SE, Buchanan GR: Vascular complications after splenectomy for
179. Berger F, Felman P, Thieblemont C, et al: Non-MALT marginal zone hematologic disorders. Blood 114:2861, 2009.
B-cell lymphomas: a description of clinical presentation and outcome 201. Olszewski AJ: Survival outcomes with and without splenectomy in
in 124 patients. Blood 95:1950, 2000. splenic marginal zone lymphoma. Am J Hematol 87:E119, 2012.
180. Chacon JI, Mollejo M, Munoz E, et al: Splenic marginal zone lym- 202. Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al: Treatment of
phoma: clinical characteristics and prognostic factors in a series of 60 splenic marginal zone lymphoma: should splenectomy be abandoned?
patients. Blood 100:1648, 2002. Leuk Lymphoma 55:1463, 2014.
181. Salido M, Baro C, Oscier D, et al: Cytogenetic aberrations and their 203. Martin P, Rutherford S, Leonard JP: Splenic lymphomas: is there
prognostic value in a series of 330 splenic marginal zone B-cell lym- still a role for splenectomy? Oncology (Williston Park) 26:204,
phomas: a multicenter study of the Splenic B-Cell Lymphoma Group. 2012.
Blood 116:1479, 2010. 204. Bolam S, Orchard J, Oscier D: Fludarabine is effective in the treatment
182. Farrell AM, Stern SC, El-Ghariani K, et al: Splenic lymphoma with of splenic lymphoma with villous lymphocytes. Br J Haematol 99:158,
villous lymphocytes presenting as leucocytoclastic vasculitis. Clin Exp 1997.
Dermatol 24:19, 1999. 205. Lefrere F, Hermine O, Belanger C, et al: Fludarabine: an effective
183. Saadoun D, Suarez F, Lefrere F, et al: Splenic lymphoma with villous treatment in patients with splenic lymphoma with villous lymphocytes.
lymphocytes, associated with type II cryoglobulinemia and HCV infec- Leukemia 14:573, 2000.
tion: a new entity? Blood 105:74, 2005. 206. Lefrere F, Hermine O, Francois S, et al: Lack of efficacy of
184. Hermine O, Lefrere F, Bronowicki JP, et al: Regression of splenic 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with
lymphoma with villous lymphocytes after treatment of hepatitis C villous lymphocytes. Leuk Lymphoma 40:113, 2000.
virus infection. N Engl J Med 347:89, 2002. 207. Virchis A, Mehta A: Splenic lymphoma with villous lymphocytes
185. Bates I, Bedu-Addo G: Chronic malaria and splenic lymphoma: clues (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol
to understanding lymphoma evolution. Leukemia 11:2162, 1997. 100:609, 1998.
186. Isaacson PG, Piris MA, Berger F, et al: Splenic marginal zone lym- 208. El Weshi A, Ribrag V, Girinski T, et al: Low and medium dose
phoma. In Swerdlow SH, Campo E, Harris NL, et al, editors: WHO spleen radiation therapy are able to induce long-term responses in
classification of tumours of haematopoietic and lymphoid tissues, Lyon, splenic lymphoma with villous lymphocytes. Br J Haematol 103:1212,
France, 2008, International Agency for Research on Cancer, p 185. 1998.